Navigation Links
Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
Date:6/21/2010

BEIJING, June 21 /PRNewswire/ -- OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

In the investigator-initiated, single center, all-comers POTENT (Paclitaxel-eluting ballOon and bio-engineered progeniTor cEll-attracting stainless steel steNT in percutaneous treatment of coronary artery stenosis) registry, 32 percent of patients were diabetic, 86 percent were male, 58 percent had a previous myocardial infarction and the mean age of the study population was 56 years. Of the lesions treated, 46 percent were type B2/C lesions.  The patients received a pre-loading of dual antiplatelet therapy (DAPT) at least six hours prior to the percutaneous coronary intervention, and the DAPT was continued for three months. There were no in-hospital or 30 day major adverse cardiac events (MACE) reported.  There was one case of late stent thrombosis.

In the six-month clinical follow-up of the 50 patients in the study, the MACE rate was six percent, and the clinical driven target lesion revascularization (TLR) rate was four percent. In an optional nine-month angiographic follow-up of 35 patients, no patients exhibited binary restenosis. Alan Yean Yip Fong, M.D., of the Sarawak General Hospital in Malaysia presented the data during the World Congress of Cardiology Scientific Sessions 2010 in Beijing.

"We are very encouraged by the low MACE and binary restenosis rates, which are comparable to other stenting strategies and demo
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ( ... of equipment for the testing of marijuana potency ... the new Luminary™ Profiler, the industry,s first product ... in a cost-effective, portable unit. Designed ... needs of the cannabis industry, the Luminary™ Profiler ...
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington is ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) ... Atrial fibrillation is the most common cardiac arrhythmia ... some cases can lead to stroke and possible death. More ... have atrial fibrillation and the numbers are rapidly ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... 2011 ORTHOCON, Inc., a developer of implantable products designed ... bone, today announced the U.S. launch of its first commercial ... The HEMA SORB Absorbable Bone Hemostat Matrix ... putty that is designed to rapidly stop bleeding when applied ...
... Reportlinker.com announces that a new market ... Drug Device Combination Market ... the New Business Model for Growth and ... Drug Device Combination Market to ...
Cached Medicine Technology:ORTHOCON® Announces U.S. Market Launch of HEMASORB® 2Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability 2Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability 3
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga started ... in its Goa retreat . This is the third ... from November to March, Siddhi Yoga will organize four yoga ... The Goa training sessions will conclude in March 2015. ... the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... The Hermitage Club at Haystack Mountain, ... Deerfield Valley, announced today that it has unveiled its ... , Three time Grammy Award Winner Kenny Loggins ... by a trail naming ceremony. Hermitage Club Founder, President ... Alright” the theme song for the movie soundtrack to ...
(Date:12/19/2014)... Randy Dotinga HealthDay ... -- Common painkillers, including ibuprofen, might slightly reduce your ... say. Use of ibuprofen (Advil, Motrin) and naproxen ... skin cancer by 15 percent, the researchers concluded after ... usually caused by sun exposure. These ...
(Date:12/17/2014)... Nwe is the co-author of a new weight loss book ... the Ace Medical Weight Loss Center in Rock Hill, SC. ... the industry of weight loss, and how several fad diets ... television shows, however, she says the topic of obesity is ... basic laughs, which she believes impacts whether Americans view it ...
(Date:12/17/2014)... December 17, 2014 In its comprehensive ... and its Argus Claim Review division have recently identified ... most common ways savings are achieved on behalf of ... millions of dollars in savings to Argus each year, ... , As explained by Tom Doney, Cypress president and ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2
... tumor which is found resistant to most of the ... The main causative agents for the development of Malignant ... virus 40 (SV40) is also found to be a ... people with malignant mesothelioma have worked or lived in ...
... children sustain at home can be of a grave nature ... result in deaths. ,Researchers at Cincinnati Children's Hospital Medical Center ... the journal Pediatrics// said that preventable injuries sustained at home ... They have studied the results taken from the National Vital ...
... genetic expressions by silencing some expressions of the gene.// ... and health conditions., ,Researchers at UT Southwestern Medical ... produce a drug for the treatment or cure of ... the online edition of the journal Nature Chemical Biology, ...
... and diligence in Britain of Indian origin hit headlines after ... the UK is well known for its long waiting lists ... a routine operation. This has brought NHS under criticism. ... had other ideas on how to deal with the waiting ...
... be easier to diagnose strokes affecting the left-brain than ... issue of The Lancet.// ,The authors state that ... symptoms of right-brain stroke. ,Cerebrovascular events are frequently ... of the brain the lesion occurs. People with events ...
... a recent study published for the first time, researchers ... oxidized phospholipids and the risk of coronary artery disease ... those of Lp(a) lipoprotein, the researchers suggest that that ... may be partly mediated by the proinflammatory oxidized phospholipids ...
Cached Medicine News:Health News:Malignant Mesothelioma – A New Genetic Revelatio 2Health News:Malignant Mesothelioma – A New Genetic Revelatio 3Health News:Indian Surgeon Conducts 70 Surgeries During His Holidays In England 2Health News:Stroke In The Right-Brain Can Remain Undiagnosed 2Health News:The Link Between Oxidized Phospholipids And Coronary Artery Disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: